Literature DB >> 24282038

Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.

Marta Ragonese1, Angela Alibrandi, Gianluca Di Bella, Ignazio Salamone, Soraya Puglisi, Oana Ruxandra Cotta, Maria Luisa Torre, Francesco Ferrau, Rosaria Maddalena Ruggeri, Francesco Trimarchi, Salvatore Cannavo.   

Abstract

Prediction of ischemic cardiovascular events (ICE) in acromegalic patients stratified accordingly with Framingham (FS) and Agatston score (AS). 32 patients with active (group A (0)) and 20 with controlled (group B (0)) acromegaly have been enrolled. During the 5-year follow-up, 19 out of 32 patients in group A (0) reached disease control. At entry, FS and AS, by an eight-slice MDCT scanner, were calculated in all patients. ICE were diagnosed by autopsy, if lethal, and by electrocardiography and/or echocardiography, if non-lethal. Overall, 9.6 % of patients died for lethal ICE. AS >400, but not high FS at entry, was associated with increased risk of lethal ICE. Lethal ICE had occurred in two patients of group A (0) and three of group B (0) (p NS), while a non-lethal ICE had occurred in two cases of the former and in other two of the latter group (p NS). Either FS or AS was correlated with the risk for ICE overall (p < 0.02), but only AS correlated with that of lethal ICE (p < 0.0003). Survival analysis demonstrated reduced life expectancy in patients with high FS (p < 0.02). In acromegalics, AS >400 is associated with increased risk of lethal ICE, while high FS is associated with reduced life expectancy, regardless of disease control.

Entities:  

Mesh:

Year:  2013        PMID: 24282038     DOI: 10.1007/s12020-013-0115-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  26 in total

Review 1.  Cardiovascular function in acromegaly.

Authors:  R N Clayton
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

2.  ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography).

Authors:  Philip Greenland; Robert O Bonow; Bruce H Brundage; Matthew J Budoff; Mark J Eisenberg; Scott M Grundy; Michael S Lauer; Wendy S Post; Paolo Raggi; Rita F Redberg; George P Rodgers; Leslee J Shaw; Allen J Taylor; William S Weintraub; Robert A Harrington; Jonathan Abrams; Jeffrey L Anderson; Eric R Bates; Cindy L Grines; Mark A Hlatky; Robert C Lichtenberg; Jonathan R Lindner; Gerald M Pohost; Richard S Schofield; Samuel J Shubrooks; James H Stein; Cynthia M Tracy; Robert A Vogel; Deborah J Wesley
Journal:  Circulation       Date:  2007-01-12       Impact factor: 29.690

3.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

Review 4.  Pegvisomant in acromegaly: why, when, how.

Authors:  A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 5.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

6.  Acromegaly per se does not increase the risk for coronary artery disease.

Authors:  Hiroyoshi Akutsu; Jürgen Kreutzer; Gerald Wasmeier; Dieter Ropers; Christian Rost; Matthias Möhlig; Henri Wallaschofski; Michael Buchfelder; Christof Schöfl
Journal:  Eur J Endocrinol       Date:  2010-02-09       Impact factor: 6.664

7.  A nationwide survey of mortality in acromegaly.

Authors:  Ritva Kauppinen-Mäkelin; Timo Sane; Antti Reunanen; Matti J Välimäki; Leo Niskanen; Helene Markkanen; Eliisa Löyttyniemi; Tapani Ebeling; Pia Jaatinen; Hanna Laine; Pirjo Nuutila; Pasi Salmela; Jorma Salmi; Ulf-Håkan Stenman; Jorma Viikari; Erkki Voutilainen
Journal:  J Clin Endocrinol Metab       Date:  2005-05-10       Impact factor: 5.958

8.  Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.

Authors:  S Cannavò; S Squadrito; L Curtò; B Almoto; F Trimarchi
Journal:  Horm Metab Res       Date:  2001-10       Impact factor: 2.936

9.  AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.

Authors:  Marie Bex; Roger Abs; Guy T'Sjoen; Jean Mockel; Brigitte Velkeniers; Katja Muermans; Dominique Maiter
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

10.  Impact of disease duration on coronary calcification in patients with acromegaly.

Authors:  B L Herrmann; M Severing; A Schmermund; C Berg; Th Budde; R Erbel; K Mann
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-04-16       Impact factor: 2.949

View more
  11 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Optimal use of pegvisomant in acromegaly: are we getting there?

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2014-10-28       Impact factor: 3.633

3.  Insight into cardiovascular risk factors in patients with acromegaly.

Authors:  Maria Fleseriu
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

Review 4.  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Authors:  Federico Gatto; Claudia Campana; Francesco Cocchiara; Giuliana Corica; Manuela Albertelli; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Massimo Giusti; Diego Ferone
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

5.  Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.

Authors:  Dilek Arpaci; Sevim Karakas Celik; Murat Can; Esra Ermiş; Fatih Kuzu; Furuzan Kokturk; Ayse Ceylan Hamamcioglu; Ahmet Dursun; Taner Bayraktaroglu
Journal:  Redox Rep       Date:  2016-02-15       Impact factor: 4.412

6.  Low risk of coronary artery disease in patients with acromegaly.

Authors:  Cintia Marques Dos Santos Silva; G A B Lima; I C M Volschan; I Gottlieb; L Kasuki; L Vieira Neto; M R Gadelha
Journal:  Endocrine       Date:  2015-05-17       Impact factor: 3.633

Review 7.  Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis.

Authors:  Matteo Parolin; Francesca Dassie; Chiara Martini; Roberto Mioni; Lucia Russo; Francesco Fallo; Marco Rossato; Roberto Vettor; Pietro Maffei; Claudio Pagano
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

Review 8.  The Endothelium in Acromegaly.

Authors:  Pietro Maffei; Francesca Dassie; Alexandra Wennberg; Matteo Parolin; Roberto Vettor
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-24       Impact factor: 5.555

Review 9.  Advances in Research on the Cardiovascular Complications of Acromegaly.

Authors:  Han Yang; Huiwen Tan; He Huang; Jianwei Li
Journal:  Front Oncol       Date:  2021-04-02       Impact factor: 6.244

Review 10.  Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.

Authors:  Soraya Puglisi; Francesco Ferraù; Marta Ragonese; Federica Spagnolo; Salvatore Cannavò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-06       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.